Podcasts about us medical affairs

This episode features an interview with Carlos Doti, MD, Vice President, US Medical Affairs Oncology, AstraZeneca, about new breast cancer treatments.Dr. Doti is a hematologist by training and is passionate about developing treatments that have a real impact for people living with cancer across every aspect of their disease. Dr. Doti has worked in industry for the last 14 years, including seven years at AstraZeneca in various roles, and in small markets like Argentina as well as larger global markets. Since 2022, Dr. Doti has been focusing on the US market in hematology and oncology, working in breast, lung, GI and gynecological cancers among others.Dr. Doti has previously served in medical affairs roles at Novo Nordisk A/S and Pfizer. His work is supported by more than 70 congress presentations and several peer-reviewed publications. He has also served as an investigator in more than 25 clinical trials in hemostasis, onco-hematology and infectious disease.Recently, AstraZeneca won approval for the company's AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1, or PTEN). The approval of Truqap was the first-in-class approval for AstraZeneca.Tune into the episode to hear more about the milestone approval of the new combination breast cancer treatment, which has been a much-needed treatment option for the nearly 50 percent of patients with advanced HR-positive breast cancer who have PIK3CA and AKT1 mutations or PTEN alterations, and experience resistance to first-line treatments such as endocrine therapies and CDK 4/6 inhibitors. For more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Join us on the mibo show for an enlightening episode with David Banner, a renowned Hip-Hop artist, actor, activist, and health advocate. He shares his mental health journey and discusses health disparities, while emphasizing the importance of regular check-ups and self-care. We are also joined by Dr. JaBaris D. Swain, Medical Executive, US Medical Affairs, Cardiovascular & Metabolism, Pharmaceuticals at Johnson & Johnson.Shanti Das, David Banner, and Dr. Swain delve into the significance of proactive mental health management, the power of early detection, and how taking charge of your health can lead to a better quality of life. They discuss the obstacles that can prevent individuals from seeking medical care and the ways we can overcome these barriers to prioritize our well-being.Tune in for motivation to take control of your mental health and advocate for wellness in your community. Subscribe for this transformative conversation on self-care and resilience.Resources:Our Race to Health Equity (ORTHE): https://www.jnj.com/our-race-to-health-equityDepression Looks Like Me: https://www.depressionlookslikeme.comMy Health Can't Wait (MHCW): https://www.myhealthcantwait.comPlease support Shanti Das' non-profit: https://www.silencetheshame.com

Join us as we unpack the story of how Erick Sermon (of legendary rap group EPMD), known for his dynamic music production and iconic collaborations, found himself facing a critical health challenge that reshaped his perspective on life. Discover how his personal experience with heart issues led him to become a powerful voice in promoting cardiovascular health within the Hip-Hop community. We are also joined by Dr. JaBaris D. Swain, Medical Executive, US Medical Affairs, Cardiovascular & Metabolism, Pharmaceuticals at Johnson & Johnson. Dr. Swain shares his inspiring dedication to provide patients with important education and quality care to keep their heart healthy.Resources:Johnson & Johnson Heart Health Newsletters: https://www.jnj.com/allyourlife/heart-healthOur Race to Health Equity (ORTHE): https://www.jnj.com/our-race-to-health-equityGet Smart About AFib: https://getsmartaboutafib.net/en-USMy Health Can't Wait / Heart Health: https://www.myhealthcantwait.com/resources/heart-healthPlease support Shanti Das' non-profit: https://www.silencetheshame.com 

Are you leading or building a Medical Affairs organization? This month Peg had a great conversation with Janet Loesberg where they discussed leadership and the barriers to success in Medical Affairs. Janet Loesberg, PharmD, Senior Vice-President of Global Medical Affairs at Blueprint Medicine, and a biotech board member, brings many years of experience, holding a variety of leadership positions in the pharmaceutical industry. She delivers great advice and perspectives focused on leading in Global and US Medical Affairs, building a team with the right person matched to the right role, and ensuring communication across the team. Dr. Peg Crowley-Nowick as Head of Medical Affairs at Lumanity has worked with many teams to support leadership development. She adds her perspective and experience while facilitating this podcast.3

This episode features Mena Boules, MD Executive Medical Director, Gastroenterology, US Medical Affairs at Takeda Pharmaceuticals discusses his career transition, how he has paid it forward and found success in Medical Affairs We discuss….

Leading experts from the SLE Educators' Network discuss how biologic therapies may help address key unmet needs in lupus, while highlighting how clinicians can identify the most appropriate patients for biologic treatment.

In October (Breast Cancer Awareness Month), many women schedule annual mammograms as a result of the national spotlight on breast health and breast cancer risk. But what happens if a mammogram identifies dense breast tissue? Nearly half of women aged 40 and over who have mammograms are told they have dense breasts, which can increase risk of breast cancer. For women with the densest breasts, the risk for breast cancer can be four to six times higher than women with the least dense breasts. Dr. Pamela Habib; Head of US Medical Affairs, Bayer Radiology and Dr. David Schacht; Breast Radiologist at Northwestern's Lynne Sage Breast Center at Prentice Women's Hospital join Michelle to talk about the importance of screenings and what it means for women with dense breasts.By age 60, half of men suffer from benign prostatic hyperplasia (BPH), also known as enlarged prostate. The common condition causes patients to experience difficultly starting and stopping urination, feeling a frequent or urgent need to pee, and being unable to completely empty their bladder.Rezūm™ Water Vapor Therapy is a non-surgical treatment for men 50 years or older that can be performed in a doctor's office. Dr. Rahul Mehan from the East Valley Urology Center of Arizona talks about signs and symptoms of an enlarged prostate and new treatments available.Arin Schultz is director at Naturepedic. Naturepedic makes organic bedding for babies, kids and adults. So often we want what's best for our kids, but do we think about the type of bed we are sleeping on? Arin talk about the benefits of organic mattresses and the different products from Naturepedic. If you head to their website and use promocode PASSPORT15, you'll receive 15% off the entire website! www.naturepedic.comKhaliah Ali is a healthcare advocate, activist, designer, author and daughter of former professional boxer Muhammad Ali. She discusses how the Black community has been disproportionately affected by obesity, social risk factors of obesity among Black American women and what appropriate interventions look like.

What is Breast Density? How dangerous is it for women? What happens if a mammogram identifies dense breast tissue? These and many more critical questions for Dr. Pamela Habib Head of US Medical Affairs at Bayer Radiology.BIO ~PAMELA HABIB Dr. Habib leads the US Medical Affairs team at Bayer Radiology and oversees engagement with healthcare professionals, communication of scientific data, and various educational and research initiatives. Dr. Habib is a Breast Radiologist, who completed her breast imaging fellowship at Harvard Medical School's Brigham & Women's Hospital. In clinical practice she focused on mammography, MRI, ultrasound, and breast interventional procedures.

What is Breast Density? How dangerous is it for women? What happens if a mammogram identifies dense breast tissue? These and many more critical questions for Dr. Pamela Habib Head of US Medical Affairs at Bayer Radiology.BIO ~PAMELA HABIB Dr. Habib leads the US Medical Affairs team at Bayer Radiology and oversees engagement with healthcare professionals, communication of scientific data, and various educational and research initiatives. Dr. Habib is a Breast Radiologist, who completed her breast imaging fellowship at Harvard Medical School's Brigham & Women's Hospital. In clinical practice she focused on mammography, MRI, ultrasound, and breast interventional procedures.

October is Breast Cancer Awareness Month and we have special guests Dr. Pamela Habib (Head of US Medical Affairs, Bayer Radiology) and Dr. David Schacht (Breast Radiologist at Northwestern's Lynne Sage Breast Center at Prentice Women's Hospital) joining us to discuss the topic of breast density. Many women schedule annual mammograms as a result of the national spotlight on breast health and breast cancer risk. But what happens if a mammogram identifies dense breast tissue? Nearly half of women aged 40 and over who have mammograms are told they have dense breasts, which can increase risk of breast cancer. For women with the densest breasts, the risk for breast cancer can be four to six times higher than women with the least dense breasts.

Nearly half of all women aged 40+ who have mammograms are told they have dense breasts. Yet, many women don't know that having dense breasts can increase their risk of breast cancer.[i] Dr. Pamela Habib; Head of US Medical Affairs, Bayer Radiology and Dr. David Schacht, Breast Radiologist at Northwestern's Lynne Sage Breast Center at Prentice Women's Hospital have information about what women need to know breast cancer.

Nearly half of all women aged 40+ who have mammograms are told they have dense breasts. Yet, many women don't know that having dense breasts can increase their risk of breast cancer.[i] Dr. Pamela Habib; Head of US Medical Affairs, Bayer Radiology and Dr. David Schacht, Breast Radiologist at Northwestern's Lynne Sage Breast Center at Prentice Women's Hospital have information about what women need to know breast cancer.

Did you know nearly half of all women aged 40+ who have mammograms are told they have dense breasts? What's a gal supposed to do with that information?  Pay more attention to her breast health for one. Many women have no clue that having dense breasts can increase their risk of breast cancer. Dense breasts can also make cancer more difficult to detect on a mammogram, leading to missed or underdiagnosed cancers, which can contribute to breast cancer mortality.  Bayer Radiology released new survey results that uncovered gaps in knowledge among women with dense breasts, pointing to a greater need for education on this important women's health topic. Joining me in this short but important podcast to help educate you are Dr. Pamela Habib; Head of US Medical Affairs, Bayer Radiology and Dr. David Schacht; Breast Radiologist at Northwestern's Lynne Sage Breast Center at Prentice Women's Hospital. This is important information for women over 40. Please share it. PERSONAL NOTE: I'm a Breast Cancer survivor who had dense breasts. I felt a lump and my first stop in my long journey was a radiologist who found the cancer. I'm grateful to still be here so I can educate others. 

Dr. Pamela Habib, head of US Medical Affairs at Bayer Radiology and Dr. David Schacht, Breast Radiologist at Northwesterern's Lynne Sage Breast Center discuss the all-important topic of Breast Cancer and the issue of 'Dense Breasts' and its impact on breast cancer risk.About Dr. Pamela Habib:   Dr. Habib leads the US Medical Affairs team at Bayer Radiology and oversees engagement with healthcare professionals, communication of scientific data, and various educational and research initiatives. Dr. Habib is a Breast Radiologist who completed her breast imaging fellowship at Harvard Medical School's Brigham & Women's Hospital. In clinical practice, she focused on mammography, MRI, ultrasound, and breast interventional procedures. About David Schacht:   Dr. David Schacht is a breast radiologist at Northwestern's Lynne Sage Breast Center at Prentice Women's Hospital.  He has been an attending physician both at Northwestern, and previously at the University of Chicago.  He obtained his undergraduate, medical, and public health degrees all from Northwestern before pursuing his radiology residency and breast imaging fellowship at the University of Chicago. His academic interests include understanding new uses of MRI to detect breast cancer and the use of case-based learning to improve the performance of radiologists.    For more information please visit: https://radiologyresources.bayer.com/dense-breast-resources

Dr. Pamela Habib, head of US Medical Affairs at Bayer Radiology and Dr. David Schacht, Breast Radiologist at Northwesterern's Lynne Sage Breast Center discuss the all-important topic of Breast Cancer and the issue of 'Dense Breasts' and its impact on breast cancer risk.About Dr. Pamela Habib:   Dr. Habib leads the US Medical Affairs team at Bayer Radiology and oversees engagement with healthcare professionals, communication of scientific data, and various educational and research initiatives. Dr. Habib is a Breast Radiologist who completed her breast imaging fellowship at Harvard Medical School's Brigham & Women's Hospital. In clinical practice, she focused on mammography, MRI, ultrasound, and breast interventional procedures. About David Schacht:   Dr. David Schacht is a breast radiologist at Northwestern's Lynne Sage Breast Center at Prentice Women's Hospital.  He has been an attending physician both at Northwestern, and previously at the University of Chicago.  He obtained his undergraduate, medical, and public health degrees all from Northwestern before pursuing his radiology residency and breast imaging fellowship at the University of Chicago. His academic interests include understanding new uses of MRI to detect breast cancer and the use of case-based learning to improve the performance of radiologists.    For more information please visit: https://radiologyresources.bayer.com/dense-breast-resources

Every cell in your body has genes that contain the blueprints, or genetic code, for your body. Cancer develops when changes – or mutations -- in some of these genes cause the cells to grow uncontrollably and take on new characteristics. Tumor profiling, also called molecular profiling or genomic testing, gives information about the specific changes in the genes of cancer cells. Today we are joined by Dr. Christy Russell, Vice President of US Medical Affairs at Exact Sciences, who will talk with us about tumor profiling in breast cancer. Welcome to the show, Christy!

Genentech US Medical Affairs is involved in hundreds of concurrent clinical trials that involve a spectrum of participants and investigators. The world of clinical trials and therapy development has been evolving and now COVID-19 is forcing the industry to innovate in different ways as it deals with labor shortages, supply chain disruptions, and a new virtual-first patient engagement environment. Nik Kolatkar, Vice President, Scientific Operations, US Medical Affairs at Genentech sat down with Greg Kefer to discuss his vision for reimagining the way trials are executed. In order to meet modern consumer expectations, Genentech is leveraging advanced conversational AI to engage trial participants, to diversify, to democratize, and to create a constant feedback mechanism — all made possible through simple, smart, interactive messaging on smartphones.   Nik also describes the Genentech Innovation Hub strategy and how that team takes a startup mindset predicated on looking horizontally across the organization to achieve small, quick wins and then scaling the technology that works across the entire project portfolio.

Genentech US Medical Affairs is involved in hundreds of concurrent clinical trials that involve a spectrum of participants and investigators. The world of clinical trials and therapy development has been evolving and now COVID-19 is forcing the industry to innovate in different ways as it deals with labor shortages, supply chain disruptions, and a new virtual-first patient engagement environment. Nik Kolatkar, Vice President, Scientific Operations, US Medical Affairs at Genentech sat down with Greg Kefer to discuss his vision for reimagining the way trials are executed. In order to meet modern consumer expectations, Genentech is leveraging advanced conversational AI to engage trial participants, to diversify, to democratize, and to create a constant feedback mechanism — all made possible through simple, smart, interactive messaging on smartphones.   Nik also describes the Genentech Innovation Hub strategy and how that team takes a startup mindset predicated on looking horizontally across the organization to achieve small, quick wins and then scaling the technology that works across the entire project portfolio.

Women In Government Podcast Type 2 Inflammation: Health Disparities & Impact on Minority Populations People living with type 2 inflammatory diseases often feel limited by unpredictable symptoms and isolated in their experiences. For example, the condition can contribute to the debilitating itch of atopic dermatitis or (AD), and sometimes life-threatening asthma attacks, or the loss of smell and taste associated with chronic rhinosinusitis or (CRS) with nasal polyps. Living with these chronic diseases and searching for control, people have looked for answers and found few. On this episode of the Women In Government Podcast, our panel discusses the health disparities of this chronic condition, the disproportionate impact on minority populations, and the prevalence of this disease across the country. ••••• ••••• ••••• MODERATOR: Illinois State Senator, Mattie Hunter, Midwestern Regional Director, WIG Board of Directors GUEST #1: Dr. Gary Puckrein, Ph.D., President, National Minority Quality Forum (NMQF) GUEST #2: Kenny Mendez, CEO and President, the Asthma and Allergy Foundation of America (AAFA) GUEST #3: Dr. Debra Sierka, PharmD., Head of Dermatology, US Medical Affairs, Sanofi Genzyme ••••• ••••• ••••• For more information, please visit www.womeningovernment.org Audio courtesy of OSUCHLUCK Productions, www.osuchluck.com

Going through the fellowship interview process at Midyear poses many challenges: keeping track of timelines, preparing for interviews, staying calm under pressure, feeling confident in your responses and decisions - the list goes on and on. Thankfully, IPhO Podcast episode 9 offers some important guidance to help you prepare. On this episode, Aleksey is joined by Preston Skersick, a current US Medical Affairs Fellow at GSK/UNC. They both share tips and tricks that helped them navigate the fellowship interview process and land the positions they really wanted.

The race to develop a COVID-19 vaccine shined a light on an issue that has challenged the pharmaceutical industry for years. Underrepresented minority communities are often disproportionately impacted by diseases, yet those groups are usually underrepresented in the clinical trials that are designed to assess the effectiveness of drugs that they need. As one of the world's largest biotechnology companies, Genentech is tapping advanced mobile technology to help increase the diversity of trial participants and improve the experience. In this episode of Digital Conversations, Nik Kolatkar, VP of Evidence Generation, US Medical Affairs at Genentech, joined Greg Kefer for a discussion about clinical trial innovation.  Genentech runs a portfolio of 500 trials around the world and is using advanced technology to drive trust, education, and convenience for participants. Through smart, language-based interactions, digital navigators eliminate the need for participants to report to ivory tower academic centers and instead, provide the capabilities for anyone to be part of bringing advanced science to their communities, regardless of location, race, gender, income, or age.

The race to develop a COVID-19 vaccine shined a light on an issue that has challenged the pharmaceutical industry for years. Underrepresented minority communities are often disproportionately impacted by diseases, yet those groups are usually underrepresented in the clinical trials that are designed to assess the effectiveness of drugs that they need. As one of the world's largest biotechnology companies, Genentech is tapping advanced mobile technology to help increase the diversity of trial participants and improve the experience. In this episode of Digital Conversations, Nik Kolatkar, VP of Evidence Generation, US Medical Affairs at Genentech, joined Greg Kefer for a discussion about clinical trial innovation.  Genentech runs a portfolio of 500 trials around the world and is using advanced technology to drive trust, education, and convenience for participants. Through smart, language-based interactions, digital navigators eliminate the need for participants to report to ivory tower academic centers and instead, provide the capabilities for anyone to be part of bringing advanced science to their communities, regardless of location, race, gender, income, or age.

it is indeed a known fact that entire world have been ravaged with a severe viral infectious disease that has claimed millions of lives. Take a Listen to this insightful and informative "HEALTH & WELLNESS" segment with Dr. Bilikis - Medical Analytics Director for US Medical Affairs at GlaxoSmithKline (GSK). --- Send in a voice message: https://anchor.fm/afolarin-ani/message

On April 19, 2020, our host Dr. Marianne Ritchie was joined by Edward H. Jasper, MD and Richard Nettles, MD for a discussion about emergency preparedness and vaccines.Dr. Jasper is a Professor of Emergency Medicine at Jefferson University Hospital.Dr. Nettles is the Vice President of US Medical Affairs, Virology at Johnson & Johnson.Each week we highlight the #RealChampions in your life! Your family, friends, or colleagues who go the extra mile to help others in their community.For the week of April 19, 202, Your Real Champions were Liz Hagedorn and Erin Hill!